Pure mucinous adenocarcinoma of the breast with the rare lymphoplasmacytic infiltration: A case report with review of literature
We present the case of a 55-year-old female with a 15-year history of a painless, gradually enlarging palpable lump on her left breast. Upon examination, a 5 × 5 cm lump with well-defined margins and a hard consistency was found in the lower outer quadrant of the left breast. Histopathological examination confirmed a diagnosis of Mucinous Adenocarcinoma of the Left Breast. The patient underwent modified radical mastectomy and received adjuvant endocrine therapy with tamoxifen due to hormone receptor-positive status. Mucinous carcinoma of the breast is a unique entity with specific histological features including the prese...
Source: Clinical Genitourinary Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Yash Hasmukhbhai Prajapati Vishal Bhabhor Kahan Samirkumar Mehta Mithoon Barot Husen Boriwala Mohamed Omar Source Type: research
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Lancet Oncol. 2024 Apr;25(4):474-487. doi: 10.1016/S1470-2045(24)00034-2.ABSTRACTBACKGROUND: The PI3K-mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)-mTOR complex 2 (mTORC2) with endocrine therapy and a CDK4/6 inhibitor might provide more effective tumour control than standard-of-care therapy. To evaluate this hypothesis, gedatolisib, a pan-PI3K-mTOR inhibitor, was assessed in a phase 1b trial combined with palbociclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. Resul...
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Rachel M Layman Hyo S Han Hope S Rugo Erica M Stringer-Reasor Jennifer M Specht E Claire Dees Peter Kabos Samuel Suzuki Sarah C Mutka Brian F Sullivan Igor Gorbatchevsky Robert Wesolowski Source Type: research
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
ConclusionsIn this systematic review, data from RCTs showed that palbociclib was effective, well tolerated, and maintained QoL in older patients with HR+/HER2 − a/mBC. Palbociclib treatment in older patients in real-world settings was associated with similar clinical benefit as in RCTs.PROSPERO RegistrationCRD42023444195. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research
Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota
Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on this strategy as a primary treatment, with promising results. The impact of the microbiota on cancer, and vice-versa, is an emerging topic in oncology. The authors report a clinical case of a postmenopausal female patie...
Source: Frontiers in Oncology - March 27, 2024 Category: Cancer & Oncology Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
Challenges in Obtaining and Seeking Information Among Breast Cancer Survivors in an Asian Country: a Qualitative Study
This study aimed to understand the challenges in obtaining and seeking information among Malaysian breast cancer survivors. We conducted semi-structured, one-to-one interviews among patients using AET from two hospitals and a local cancer organization. Interviews were conducted until theme saturation was achieved (N = 25). Interviews were de-identified, transcribed verbatim, and analysed using thematic analysis. To ensure rigor, coding was conducted through regular discussions between two researchers and the findings were shared with several participants after analysis was completed. Three main themes were identified: limi...
Source: Journal of Cancer Education - March 26, 2024 Category: Cancer & Oncology Source Type: research
Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden
ConclusionDifferent surgical strategies, age, and body mass index did not impact on ESAS scores, while the type of adjuvant systemic therapy did. The effect of previous neoadjuvant treatment and unfavorable tumor biology (triple negative) emerged as important factors associated with symptom burden, albeit in different domains. ESAS data may facilitate identification of patients who should be considered for additional supportive measures to alleviate specific symptoms. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - March 26, 2024 Category: Cancer & Oncology Source Type: research
